Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-15

Study Completion Date

2019-06-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, the prevalence of metabolic syndrome in psoriatic and psoriatic arthritis patients as well as the parameters of metabolic syndrome will be examined. At the same time, the levels of omentin and visfatin adipokines associated with metabolic syndrome and obesity will be measured by measuring the disease severity (by PASI psoriasis, clinical activity score for psoriatic arthritis). The patients who accepted to participate in the study , who were admitted to the dermatology outpatient clinic were included in the study. For the blood tests required after the examination, 2 tubes of blood will be taken for the measurement of omentin and visfatin. 80 psoriasis, 40 psoriatic arthritis and 60 healthy volunteers were planned to be studied. AHA / NHLBI, 2005 (revised ATP III criteria) criterion for the diagnosis of metabolic syndrome will be used. Omentin and visfatin levels are compared with the severity of the disease for psoriasis and psoriatic arthritis, and it will be examined whether it is proinflammatory or antiinflammatory.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Peds Metabolic Syndrome in Psoriasis

NCT00930592

Psoriasis Metabolic Syndrome

COMPLETED

Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

NCT00477191

Psoriasis Metabolic Syndrome Hyperlipidemia +2 more

TERMINATED NA

Association Between Biologic Therapy and Demodex Density in Psoriasis Patients: A Comparative Study

NCT05954572

Demodicidosis

UNKNOWN

Metabolic Biomarkers in Hashimoto's Thyroiditis and Psoriasis

NCT04693936

Hashimoto Disease Psoriasis

ACTIVE_NOT_RECRUITING NA

Phase I Study of GN-037 Cream for Psoriasis

NCT05428202

Psoriasis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis Vulgaris Psoriatic Arthritis Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

psoriasis vulgaris,

patients who have only psoriasis vulgaris

Group Type OTHER

omentin, visfatin

Intervention Type DIAGNOSTIC_TEST

diagnostic blood test

psoriatic arthritis

patients who have psoriatic arthritis

Group Type OTHER

omentin, visfatin

Intervention Type DIAGNOSTIC_TEST

diagnostic blood test

healthy control

healthy people

Group Type OTHER

omentin, visfatin

Intervention Type DIAGNOSTIC_TEST

diagnostic blood test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

omentin, visfatin

diagnostic blood test

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients followed up for psoriasis and psoriatic arthritis in dermatology and rheumatology clinic
2. Patients older than 18 years
3. Patients who accept dermatological and rheumatic examination
4. Patients not receiving systemic treatment related to the disease in the last 1 month

Exclusion Criteria

1. Patients with autoimmune and rheumatic diseases other than psoriasis and psoriatic arthritis
2. Patients under 18 years
3. Patients who do not accept dermatological and rheumatic examination Patients receiving systemic therapy for the last 1 month pregnant and nursing moms

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes